Daily non-political popular news in brief.

Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip

Recent data from the Lung Allograft Rejection Gene expression Observational study provides compelling evidence that profiling gene expression in peripheral blood can detect organ rejection in lung transplant patients. Refining the Identification of Discriminatory Genes for Rejection in Lung Transplantation: The LARGO Study will be presented today by Shaf Keshavjee, M.D., chair, Division of Thoracic Surgery, University of Toronto, and LARGO study lead, at the 27th annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

Read more »

Keywords: data, presented, ishlt, meeting, confirm, rna, analysis, identify, rejection, lung, transplant, recip, analysi

« Previous | Next »

Similar news on "Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip":

1. Targeted, oral agent Enzastaurin shows favorable results
   06-02-2007 · EurekAlert!
   Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
   Similar news · Read more »
   
2. New analysis shows Kadian alleviates chronic moderate-to-severe non-malignant neck pain
   11-15-2006 · EurekAlert!
   Data presented this week at the American Academy of Physical Medicine and Rehabilitation meeting, demonstrated that Kadian improved sleep and overall quality of life in patients with moderate-to-severe chronic neck pain who had inadequate relief on previous analgesic regimens. Kadian is an extended-release formulation of morphine sulfate.
   Similar news · Read more »
   
3. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
   06-02-2007 · EurekAlert!
   ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer, according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.
   Similar news · Read more »
   
4. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
   05-23-2007 · EurekAlert!
   Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
   Similar news · Read more »
   
5. Increasing survival of organ transplant patients by reducing time interval for transported organs
   04-26-2007 · EurekAlert!
   Preservation of an organ intended for transplant during transport from donor to recipient is of primary concern in ensuring a successful transplant. Research presented at the ISHLT 27th Annual Meeting and Scientific Sessions today explores two diverging systems for pump preservation -- the Organ Care System and the cold preservation method, and how they each effect survival for heart transplant patients.
   Similar news · Read more »
   
6. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
   10-23-2006 · EurekAlert!
   Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
   Similar news · Read more »
   
7. UT Southwestern researchers identify antibodies linked to kidney transplant rejection
   09-26-2007 · EurekAlert!
   UT Southwestern Medical Center researchers, collaborating with colleagues in Germany, have for the first time identified antibodies associated with transplant rejection of otherwise healthy kidneys.
   Similar news · Read more »
   
8. 'Expanded criteria nonbeating-heart' kidneys don't do well in elderly transplant patients
   11-04-2007 · EurekAlert!
   For older patients with end-stage renal disease (ESRD), the results of kidney transplants from "expanded criteria nonbeating-heart" donors are not good, according to a paper being presented at the American Society of Nephrology's 40th Annual Meeting and Scientific Exposition in San Francisco.
   Similar news · Read more »
   
9. Many adults with psychiatric disorders may also have undiagnosed ADHD
   10-27-2006 · EurekAlert!
   Shire announced today that many adults with a depressive disorder, bipolar disorder or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder, according to a longitudinal retrospective U.S. medical claims analysis presented at a medical meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
10. Results of world's first fully bioabsorable coronary artery stent clinical trial
    03-24-2007 · EurekAlert!
    Late breaking data presented at the American College of Cardiology Meeting shows positive results for world's first fully bioabsorbable coronary artery stent clinical trial.
    Similar news · Read more »